Navigation Links
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Date:10/13/2008

ncer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. OGX-011 is being evaluated in five Phase 2 clinical trials, each of which has completed patient enrollment. Interim study results have previously been presented for each of the five clinical trials.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning agreements with the FDA regarding endpoints and clinical trial design and anticipated clinical and other product development activities and timing of these activities. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumpti
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
2. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
3. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
4. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. OncoGenex increases economic interest in lead cancer drug OGX-011
7. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
10. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
11. Realtime Achieves ISO 13485:2003 Certification Targeting BioTech Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalystâ„¢ technology that enhances soil and ... segment will air again on April 28. , A ...
(Date:3/25/2015)...  S&P Capital IQ (MHFI) announced today that ... on Abattis Bioceuticals Corp . ... specialty biotechnology company with capabilities through its wholly ... ingredients, bio-similar compounds, patented equipment and consulting services ... . The company seeks to capitalize on ...
(Date:3/25/2015)... 25, 2015 An increase of awareness ... all forms of food nutrients, regulatory changes and concerns ... rise in demand for natural astaxanthin over the past ... ramp up their capacities to satisfy the rising demand. ... synthetic source astaxanthin (used in nutraceuticals, aqua feed, food ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... , , , , ... 139 human cancer-related genes for functional genomics research using , ... , , , , , ... cancer researchers (see table below for a list of genes). Every siRNA has , ...
... For purification of up to 10 mg ultrapure plasmid , or cosmid DNA , ... purification of plasmid DNA , , , ... , , ... , ...
... , , , , For robust amplification in all applications, , , , , , ... Included , Concentration , , ... , , , ... , 5 units/l , , , ...
Cached Biology Technology:Cancer siRNA Oligo Set Version 1.0 2Cancer siRNA Oligo Set Version 1.0 3Cancer siRNA Oligo Set Version 1.0 4
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/18/2015)... -- As mobile payments become more prevalent amongst ... apps continue to be introduced into the market place at ... industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Google Inc. ... FB ) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... developed analytical technique, a team led by scientists at USC ... in the ocean. "This is another twist to what ... biological and earth sciences at the USC Dornsife College of ... about the vitamin-depleted zones that will appear in Proceedings ...
... Connecticut researcher and his team have discovered that a ... blooms sometimes called "red tide" is even deadlier than ... chains. Professor Hans Dam and his research group ... that the plankton species Alexandrium tamarense contains ...
... Center for Laser Applications at the University of ... technology that goes on a "seek and destroy" ... power of lasers to find, map and non-invasively ... professor of physics, and Jacqueline Johnson, associate professor ...
Cached Biology News:Scientists confirm existence of vitamin 'deserts' in the ocean 2UConn researchers discover that 'red tide' species is deadlier than first thought 2University of Tennessee Space Institute researchers develop laser technology to fight cancer 2
HLA-DRbeta (DA2)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
... This NPY Y2 antibody has been ... currently being characerized in brain. The antibody has ... appears to work better on mose tissue, although ... characterizarion in dorsal root ganglion and spinal cord ...
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
Biology Products: